Press Room

Press Releases and Statements

Your search for Press Release returned 1000 results.

MARCH 18, 2015

New Chief Digital Officer Joins Bill & Melinda Gates Foundation

SEATTLE, WA, USA (March 19, 2015) – The Bill & Melinda Gates Foundation today announced that Todd Pierce will join the organization in the newly created role of Chief Digital Officer. He comes to the foundation from where he served as Senior Vice President of the Healthcare and Life Sciences industry. Prior to, Pierce was Chief Information Officer at Genentech and for the County of Santa Clara, California, and held technology leadership roles at Roche and Veteran’s Affairs. Additionally, he has held key positions on multiple non-profit and foundation boards.

MARCH 05, 2015

The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology

SEATTLE, WA, USA and TÜBINGEN, GERMANY (March 5, 2015) – The Bill & Melinda Gates Foundation and CureVac today announced that the foundation has made a commitment to invest $52 million (€46 million) in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA (mRNA) platform. In addition, CureVac’s longstanding investor dievini Hopp BioTech announced a commitment of $24 million (€21 million) of additional equity.

NOVEMBER 18, 2014

Gates Foundation Announces Support to Ebola-Affected Countries To Accelerate the Evaluation of Potential Treatments

SEATTLE (November 18, 2014) – The Bill & Melinda Gates Foundation today announced that it will be supporting efforts in Guinea and other Ebola-affected countries to scale up the production and evaluation of convalescent plasma and other convalescent blood products as potential therapies for people infected with the Ebola virus. Various drug candidates will also be evaluated, including the experimental antiviral drug brincidofovir.

Visit Our Blog